Actinomycin D upregulates proapoptotic protein Puma and downregulates Bcl-2 mRNA in normal peripheral blood lymphocytes

Anti-Cancer Drugs

Volumn 18, Issue 7, 2007, Pages 763-772

  Kalousek, Ivan ^a   Brodska, Barbora ^a   Otevrelova, Petra ^a   Röselova, Pavla ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

Actinomycin D; Apoptosis; Bcl 2; p53; Peripheral blood lymphocyte; Puma; Ribosomal synthesis

Indexed keywords

BH3 PROTEIN; CASPASE 3; CASPASE 7; COMPLEMENTARY DNA; DACTINOMYCIN; INHIBITOR OF APOPTOSIS PROTEIN; MESSENGER RNA; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P53; RIBOSOME DNA; RIBOSOME PROTEIN; RIBOSOME RNA;

APOPTOSIS; ARTICLE; CELL DEATH; CELL SPECIFICITY; DOWN REGULATION; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENOTOXICITY; HUMAN; HUMAN CELL; LYMPHOCYTE; MITOCHONDRION; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SYNTHESIS; TRANSCRIPTION REGULATION;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BLOTTING, WESTERN; CELL SURVIVAL; DACTINOMYCIN; DNA DAMAGE; DNA, RIBOSOMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FLOW CYTOMETRY; HUMANS; LYMPHOCYTES; MITOCHONDRIA; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 34250885082     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3280adc905     Document Type: Article

References (67)

1. Knorr C, Meyer T, Janssen T, Goehl J, Hohenberger W. Hyperthermic isolated limb perfusion (HILP) in malignant melanoma. Experience with 101 patients. Eur J Surg Oncol 2006; 32:224-227.
2. Green DM, Cotton CA, Malogolowkin M, Breslow NE, Perlman E, Miser J, et al. Treatment of Wilms tumor relapsing after initial treatment with vincristine and actinomycin D: a report from the National Wilms Tumor Study Group. Pediatr Blood Cancer 2007; 48:493-499.
3. Moschovi M, Trimis G, Stefanaki K, Anastasopoulos J, Syriopoulou V, Koultouki E, et al. Favorable outcome of Ewing sarcoma family tumors to multiagent intensive preoperative chemotherapy: a single institution experience. J Surg Oncol 2005; 89:239-243.
4. Perry RP, Kelley DE. Inhibition of RNA synthesis by actinomycin D: characteristic dose-response of different RNA species. J Cell Physiol 1970; 76:127-139.
5. Miller MJ. Sensitivity of RNA synthesis to actinomycin D inhibition is dependent on the frequency of transcription: a mathematical model. J Theor Biol 1987; 129:289-299.
6. Fraschini A, Bottone MG, Scovassi AI, Denegri M, Risueno MC, Testillano PS, et al. Changes in extranucleolar transcription during actinomycin D-induced apoptosis. Histol Histopathol 2005; 20:107-117.
7. Shav-Tal Y, Blechman J, Darzacq X, Montagna C, Dye BT, Patton JG, et al. Dynamic sorting of nuclear components into distinct nucleolar caps during transcriptional inhibition. Mol Biol Cell 2005; 16:2395-2413.
8. Dai MS, Lu H. Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5. J Biol Chem 2004; 279:44475-44482.
9. Bhat KP, Itahana K, Jin A, Zhang Y. Essential role of ribosomal protein L11 in mediating growth inhibition-induced p53 activation. EMBO J 2004; 23:2402-2412.
10. Dai MS, Zeng SX, Jin Y, Sun XX, David L, Lu H. Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition. Mol Cell Biol 2004; 24:7654-7668.
11. Jin A, Itahana K, O'Keefe K, Zhang Y. Inhibition of HDM2 and activation of p53 by ribosomal protein L23. Mol Cell Biol 2004; 24:7669-7680.
12. Shieh SY, Ikeda M, Taya Y, Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 1997; 91:325-334.
13. Giaccia AJ, Kastan MB. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev 1998; 12:2973-2983.
14. Meek DW. Mechanisms of switching on p53: a role for covalent modification? Oncogene 1999; 18:7666-7675.
15. Allison SJ, Milner J. Remodelling chromatin on a global scale: a novel protective function of p53. Carcinogenesis 2004; 25:1551-1557.
16. Coutts AS, La Thangue N. The p53 response during DNA damage: impact of transcriptional cofactors. Biochem Soc Symp 2006; 73:181-189.
17. Yu J, Zhang L. The transcriptional targets of p53 in apoptosis control. Biochem Biophys Res Commun 2005; 331:851-858.
18. Schuler M, Green DR. Mechanisms of p53-dependent apoptosis. Biochem Soc Trans 2001; 29:684-688.
19. Yakovlev AG, Di Giovanni S, Wang G, Liu W, Stoica B, Faden AI. BOK and NOXA are essential mediators of p53-dependent apoptosis. J Biol Chem 2004; 279:28367-28374.
20. Chan SL, Yu VC. Proteins of the bcl-2 family in apoptosis signalling: from mechanistic insights to therapeutic opportunities. Clin Exp Pharmacol Physiol 2004; 31:119-128.
21. Bouillet P, Strasser A. BH3-only proteins-evolutionarily conserved proapoptotic Bcl-2 family members essential for initiating programmed cell death. J Cell Sci 2002; 115:1567-1574.
22. Willis SN, Adams JM. Life in the balance: how BH3-only proteins induce apoptosis. Curr Opin Cell Biol 2005; 17:617-625.
23. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004; 116:205-219.
24. L, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 2005; 19:1294-1305.
25. Fadeel B, Zhivotovsky B, Orrenius S. All along the watchtower: on the regulation of apoptosis regulators. FASEB J 1999; 13:1647-1657.
26. Webster KA, Graham RM, Bishopric NH. BNip3 and signal-specific programmed death in the heart. J Mol Cell Cardiol 2005; 38:35-45.
27. Prasad KV, Ao Z, Yoon Y, Wu MX, Rizk M, Jacquot S, et al. CD27, a member of the tumor necrosis factor receptor family, induces apoptosis and binds to Siva, a proapoptotic protein. Proc Natl Acad Sci U S A 1997; 94:6346-6351.
28. L-mediated protection against UV radiation-induced apoptosis. Proc Natl Acad Sci U S A 2002; 99:6925-6930.
29. Debatin KM. Apoptosis pathways in cancer and cancer therapy. Cancer Immunol Immunother 2004; 53:153-159.
30. Wrzesien-Kus A, Smolewski P, Sobczak-Pluta A, Wierzbowska A, Robak T. The inhibitor of apoptosis protein family and its antagonists in acute leukemias. Apoptosis 2004; 9:705-715.
31. Zangemeister-Wittke U, Simon HU. An IAP in action: the multiple roles of survivin in differentiation, immunity and malignancy. Cell Cycle 2004; 3:1121-1123.
32. Erster S, Mihara M, Kim RH, Petrenko O, Moll UM. In vivo mitochondrial p53 translocation triggers a rapid first wave of cell death in response to DNA damage that can precede p53 target gene activation. Mol Cell Biol 2004; 24:6728-6741.
33. Fei P, Bernhard EJ, El-Deiry WS. Tissue-specific induction of p53 targets in vivo. Cancer Res 2002; 62:7316-7327.
34. Fei P, Wang W, Kim SH, Wang S, Burns TF, Sax JK, et al. Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth. Cancer Cell 2004; 6:597-609.
35. Fortin A, MacLaurin JG, Arbour N, Cregan SP, Kushwaha N, Callaghan SM, et al. The proapoptotic gene SIVA is a direct transcriptional target for the tumor suppressors p53 and E2F1. J Biol Chem 2004; 279:28706-28714.
36. Jiang M, Wei Q, Wang J, Du Q, Yu J, Zhang L, et al. Regulation of PUMA-alpha by p53 in cisplatin-induced renal cell apoptosis. Oncogene 2006; 25:4056-4066.
37. Mackall CL, Fleisher TA, Brown MR, Magrath IT, Shad AT, Horowitz ME, et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 1994; 84:2221-2228.
38. Stahnke K, Fulda S, Friesen C, Strauss G, Debatin KM. Activation of apoptosis pathways in peripheral blood lymphocytes by in vivo chemotherapy. Blood 2001; 98:3066-3073.
39. Marzluff WF, Huang RCC. Transcription of RNA in isolated nuclei. In: Hames BD, Higgins SJ, editors. Transcription and translation a practical approach. Oxford: IRL Press; 1987. pp. 89-129.
40. Kalousek I, Otevřelová P, Röselová P. Expression and translocation of major nucleolar proteins in relation to the transcriptional activity of the nucleolus. J Appl Biomed 2005; 3:175-186.
41. Hu Y, Benedict MA, Ding L, Nunez G. Role of cytochrome c and dATP/ATP hydrolysis in Apaf-1-mediated caspase-9 activation and apoptosis. EMBO J 1999; 18:3586-3595.
42. Kim HE, Du F, Fang M, Wang X. Formation of apoptosome is initiated by cytochrome c-induced dATP hydrolysis and subsequent nucleotide exchange on Apaf-1. Proc Natl Acad Sci U S A 2005; 102:17545-17550.
43. Bao Q, Shi Y. Apoptosome: a platform for the activation of initiator caspases. Cell Death Differ 2006; 14:56-65.
44. Brockstedt E, Rickers A, Kostka S, Laubersheimer A, Dorken B, Wittmann-Liebold B, et al. Identification of apoptosis-associated proteins in a human Burkitt lymphoma cell line. Cleavage of heterogeneous nuclear ribonucleoprotein A1 by caspase 3. J Biol Chem 1998; 273:28057-28064.
45. Hietanen S, Lain S, Krausz E, Blattner C, Lane DP. Activation of p53 in cervical carcinoma cells by small molecules. Proc Natl Acad Sci U S A 2000; 97:8501-8506.
46. Taha TA, Osta W, Kozhaya L, Bielawski J, Johnson KR, Gillanders WE, et al. Down-regulation of sphingosine kinase-1 by DNA damage: dependence on proteases and p53. J Biol Chem 2004; 279:20546-20554.
47. Yoo YA, Kim MJ, Park JK, Chung YM, Lee JH, Chi SG, et al. Mitochondrial ribosomal protein L41 suppresses cell growth in association with p53 and p27Kip1. Mol Cell Biol 2005; 25:6603-6616.
48. Poyurovsky MV, Priest C, Kentsis A, Borden KL, Pan ZQ, Pavletich N, et al. The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity. EMBO J 2007; 26:90-101.
49. Erlacher M, Michalak EM, Kelly PN, Labi V, Niederegger H, Coultas L, et al. BH3-only proteins Puma and Bim are rate-limiting for gamma-radiation and glucocorticoid-induced apoptosis of lymphoid cells in vivo. Blood 2005; 106:4131-4138.
50. Hutcheson J, Scatizzi JC, Bickel E, Brown NJ, Bouillet P, Strasser A, et al. Combined loss of proapoptotic genes Bak or Bax with Bim synergizes to cause defects in hematopoiesis and in thymocyte apoptosis. J Exp Med 2005; 201:1949-1960.
51. Akhtar RS, Geng Y, Klocke BJ, Latham CB, Villunger A, Michalak EM, et al. BH3-only proapoptotic Bcl-2 family members Noxa and Puma mediate neural precursor cell death. J Neurosci 2006; 26:7257-7264.
52. Kaeser MD, Iggo RD. Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proc Natl Acad Sci U S A 2002; 99:95-100.
53. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005; 17:393-403.
54. Villunger A, Michalak EM, Coultas L, Mullauer F, Bock G, Ausserlechner MJ, et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 2003; 302:1036-1038.
55. Hughes P, Bouillet P, Strasser A. Role of Bim and other Bcl-2 family members in autoimmune and degenerative diseases. Curr Dir Autoimmun 2006; 9:74-94.
56. Gomez-Bougie P, Oliver L, Le Gouill S, Bataille R, Amiot M. Melphalan-induced apoptosis in multiple myeloma cells is associated with a cleavage of Mcl-1 and Bim and a decrease in the Mcl-1/Bim complex. Oncogene 2005; 24:8076-8079.
57. Alves NL, Derks IA, Berk E, Spijker R, van Lier RA, Eldering E. The Noxa/Mcl-1 axis regulates susceptibility to apoptosis under glucose limitation in dividing T cells. Immunity 2006; 24:703-716.
58. Kitada S, Krajewska M, Zhang X, Scudiero D, Zapata JM, Wang HG, et al. Expression and location of pro-apoptotic Bcl-2 family protein BAD in normal human tissues and tumor cell lines. Am J Pathol 1998; 152:51-61.
59. Yokoyama T, Tanahashi M, Kobayashi Y, Yamakawa Y, Maeda M, Inaba T, et al. The expression of Bcl-2 family proteins (Bcl-2, Bcl-x, Bax, Bak and Bim) in human lymphocytes. Immunol Lett 2002; 81:107-113.
60. Ying S, Seiffert BM, Hacker G, Fischer SF. Broad degradation of proapoptotic proteins with the conserved Bcl-2 homology domain 3 during infection with Chlamydia trachomatis. Infect Immun 2005; 73:1399-403.
61. Donnini M, Lapucci A, Papucci L, Witort E, Tempestini A, Brewer G, et al. Apoptosis is associated with modifications of bcl-2 mRNA AU-binding proteins. Biochem Biophys Res Commun 2001; 287:1063-1069.
62. Luzi E, Papucci L, Schiavone N, Donnini M, Lapucci A, Tempestini A, et al. Downregulation of bcl-2 expression in lymphoma cells by bcl-2 ARE-targeted modified, synthetic ribozyme. Cancer Gene Ther 2003; 10:201-208.
63. Sengupta TK, Bandyopadhyay S, Fernandes DJ, Spicer EK. Identification of nucleolin as an AU-rich element binding protein involved in bcl-2 mRNA stabilization. J Biol Chem 2004; 279:10855-10863.
64. Kito S, Morimoto Y, Tanaka T, Haneji T, Ohba T. Cleavage of nucleolin and AgNOR proteins during apoptosis induced by anticancer drugs in human salivary gland cells. J Oral Pathol Med 2005; 34:478-485.
65. Otake Y, Sengupta TK, Bandyopadhyay S, Spicer EK, Fernandes DJ. Retinoid-induced apoptosis in HL-60 cells is associated with nucleolin down-regulation and destabilization of Bcl-2 mRNA. Mol Pharmacol 2005; 67:319-326.
66. Mei Y, Du W, Yang Y, Wu M. Puma(*)Mcl-1 interaction is not sufficient to prevent rapid degradation of Mcl-1. Oncogene 2005; 24:7224-7237.
67. Von Haefen C, Wieder T, Essmann F, Schulze-Osthoff K, Dorken B, Daniel PT. Paclitaxel-induced apoptosis in BJAB cells proceeds via a death receptor-independent, caspases-3/-8-driven mitochondrial amplification loop. Oncogene 2003; 22:2236-2247.